Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Perampanel in Levodopa-Treated Parkinson's Disease with Motor Fluctuations
NCT00286897Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2006
- Primary completion
- Jun 2007
- Modality
- Classical Binding Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing E2007 with Placebo (2 arms). Primary endpoint: Change in mean total daily OFF time at 30 weeks. Started Feb 2006; status: completed.
02
Drugs
perampanel
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00286897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286897.